The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Myriad Genetics Shares Surge 21% on Massive Q4 Earnings Beat

Key Facts

1Myriad Genetics stock jumped 21% after Q4 earnings beat estimates by 350%.

2Revenues topped forecasts despite a slip in gross margin and a decline in mental health sales.

Myriad Genetics (MYGN) shares skyrocketed 21% following the release of its fourth-quarter financial results. The company reported an extraordinary earnings beat, exceeding analyst estimates by a staggering 350% for the period. Revenues also outperformed market forecasts, providing a significant boost to investor sentiment despite some underlying headwinds. However, the report highlighted a slip in gross margins and a decline in sales within the mental health segment. The substantial rally reflects the market's positive reaction to the massive bottom-line surprise in the biotech sector. Investors remain focused on how the company will manage margin compression while sustaining its current revenue growth trajectory.